BR0015407A - Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para estimular a liberação de hormÈnio do crescimento da glândula pituitária de um mamìfero e para aumentar a taxa e o grau de crescimento, a produção de leite e de lã ou para o tratamento de dores, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo - Google Patents

Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para estimular a liberação de hormÈnio do crescimento da glândula pituitária de um mamìfero e para aumentar a taxa e o grau de crescimento, a produção de leite e de lã ou para o tratamento de dores, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BR0015407A
BR0015407A BR0015407-5A BR0015407A BR0015407A BR 0015407 A BR0015407 A BR 0015407A BR 0015407 A BR0015407 A BR 0015407A BR 0015407 A BR0015407 A BR 0015407A
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
growth
same
Prior art date
Application number
BR0015407-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Ankersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0015407A publication Critical patent/BR0015407A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
BR0015407-5A 1999-11-10 2000-11-10 Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para estimular a liberação de hormÈnio do crescimento da glândula pituitária de um mamìfero e para aumentar a taxa e o grau de crescimento, a produção de leite e de lã ou para o tratamento de dores, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo BR0015407A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901618 1999-11-10
US16710199P 1999-11-23 1999-11-23
PCT/DK2000/000624 WO2001034593A1 (en) 1999-11-10 2000-11-10 Compound with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
BR0015407A true BR0015407A (pt) 2002-07-02

Family

ID=26065963

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015407-5A BR0015407A (pt) 1999-11-10 2000-11-10 Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para estimular a liberação de hormÈnio do crescimento da glândula pituitária de um mamìfero e para aumentar a taxa e o grau de crescimento, a produção de leite e de lã ou para o tratamento de dores, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo

Country Status (23)

Country Link
US (1) US6576648B2 (cg-RX-API-DMAC7.html)
EP (1) EP1230236B1 (cg-RX-API-DMAC7.html)
JP (2) JP2003527338A (cg-RX-API-DMAC7.html)
KR (1) KR100907637B1 (cg-RX-API-DMAC7.html)
CN (1) CN1198818C (cg-RX-API-DMAC7.html)
AT (1) ATE280168T1 (cg-RX-API-DMAC7.html)
AU (1) AU782260B2 (cg-RX-API-DMAC7.html)
BR (1) BR0015407A (cg-RX-API-DMAC7.html)
CA (1) CA2387095C (cg-RX-API-DMAC7.html)
CZ (1) CZ301078B6 (cg-RX-API-DMAC7.html)
DE (1) DE60015173T2 (cg-RX-API-DMAC7.html)
DK (1) DK1230236T3 (cg-RX-API-DMAC7.html)
ES (1) ES2231279T3 (cg-RX-API-DMAC7.html)
HU (1) HU229445B1 (cg-RX-API-DMAC7.html)
IL (1) IL149049A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02004656A (cg-RX-API-DMAC7.html)
NO (1) NO323910B1 (cg-RX-API-DMAC7.html)
PL (1) PL199989B1 (cg-RX-API-DMAC7.html)
PT (1) PT1230236E (cg-RX-API-DMAC7.html)
RU (1) RU2272034C2 (cg-RX-API-DMAC7.html)
UA (1) UA73530C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001034593A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200202757B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735055A1 (en) * 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
US20130281701A1 (en) * 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
MXPA06015003A (es) * 2004-06-29 2007-08-07 Sapphire Therapeutics Inc Formas cristalinas de 1,2,2-trimetilhidrazida de acido (3r)-1-(2-metilalanil-d-triptofil)-3-(fenilmetil)-3- piperidincarboxilico.
AU2005272074B2 (en) * 2004-06-29 2011-11-24 Albany Molecular Research, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
JP2008509930A (ja) 2004-08-12 2008-04-03 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進物質を利用して胃腸系の運動性を刺激する方法
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
WO2008005268A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
WO2008100448A2 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US8664267B2 (en) * 2007-04-12 2014-03-04 Academic Pharmaceuticals Incorporated Parenteral solution containing amiodarone in NNDMA (N,N,-Dimethylacetamide)
PT2241564E (pt) 2008-02-08 2014-06-12 Zeria Pharm Co Ltd Derivado de 3,8-diaminotetra-hidroquinolina
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
JP6262661B2 (ja) 2012-10-24 2018-01-17 第一三共株式会社 筋萎縮性側索硬化症治療剤
CN107001323A (zh) * 2015-10-20 2017-08-01 江苏恒瑞医药股份有限公司 一种阿拉莫林的结晶形式及其制备方法
CN106187865A (zh) * 2016-07-08 2016-12-07 武汉工程大学 (r)‑1‑叔丁氧羰基‑3‑苄基‑3‑甲酸哌啶的合成及手性拆分方法
CN108129357B (zh) * 2016-12-01 2021-12-21 上海医药工业研究院 阿拉莫林中间体的制备方法
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
WO2021038519A1 (en) 2019-08-30 2021-03-04 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用
CN119792264B (zh) * 2025-03-14 2025-06-10 华中科技大学同济医学院附属同济医院 丁酰肼在制备预防或治疗copd的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
ATE122357T1 (de) 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
DE68912775T2 (de) 1988-05-11 1994-06-30 Polygen Holding Corp Polypeptid-verbindungen mit hormonwachstumsbefreiender wirkung.
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL98910A0 (en) 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
PL322706A1 (en) * 1993-11-09 1998-02-16 Merck & Co Inc Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation
WO1995014666A1 (en) 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU3434697A (en) * 1996-07-22 1998-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
IL137007A0 (en) * 1998-01-16 2001-06-14 Novo Nordisk As Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
PL194560B1 (pl) * 1998-05-11 2007-06-29 Novo Nordisk As Związki o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake

Also Published As

Publication number Publication date
HUP0203844A3 (en) 2004-07-28
CA2387095A1 (en) 2001-05-17
DE60015173T2 (de) 2005-12-08
JP2003527338A (ja) 2003-09-16
NO323910B1 (no) 2007-07-16
AU782260B2 (en) 2005-07-14
UA73530C2 (uk) 2005-08-15
KR100907637B1 (ko) 2009-07-14
HU229445B1 (en) 2013-12-30
ZA200202757B (en) 2003-02-26
CN1198818C (zh) 2005-04-27
PL199989B1 (pl) 2008-11-28
CA2387095C (en) 2011-01-11
CZ20021587A3 (cs) 2002-09-11
HUP0203844A2 (hu) 2003-03-28
KR20020059694A (ko) 2002-07-13
EP1230236A1 (en) 2002-08-14
NO20022200L (no) 2002-05-08
CZ301078B6 (cs) 2009-10-29
AU1269401A (en) 2001-06-06
IL149049A0 (en) 2002-11-10
US6576648B2 (en) 2003-06-10
NO20022200D0 (no) 2002-05-08
WO2001034593A1 (en) 2001-05-17
ES2231279T3 (es) 2005-05-16
DE60015173D1 (de) 2004-11-25
MXPA02004656A (es) 2002-09-02
PT1230236E (pt) 2005-03-31
RU2272034C2 (ru) 2006-03-20
PL356993A1 (en) 2004-07-12
JP2009062369A (ja) 2009-03-26
DK1230236T3 (da) 2005-02-21
ATE280168T1 (de) 2004-11-15
CN1420878A (zh) 2003-05-28
JP5053960B2 (ja) 2012-10-24
EP1230236B1 (en) 2004-10-20
US20010041720A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
BR0015407A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para estimular a liberação de hormÈnio do crescimento da glândula pituitária de um mamìfero e para aumentar a taxa e o grau de crescimento, a produção de leite e de lã ou para o tratamento de dores, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
Zhou et al. Modified dextrose prolotherapy for recurrent temporomandibular joint dislocation
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
BR0110420A (pt) Agonistas muscarìnicos
AU645023B2 (en) Compositions and method for treating painful, inflammatory or allergic disorders
BR0111207A (pt) Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
ATE322283T1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
BR9507227A (pt) Formulaçao farmacêutica para administraçao subcutânea intramuscular ou intradérmica uso da mesma e de um derivado de extinçao de um fator recombinante VIII e processo para o tratamento de hemofilia
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
BR0115166A (pt) Combinações de drogas (por exemplo, cloropromazina e pentamidina) para o tratamento de distúrbios neoplásticos
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
ATE173164T1 (de) Transdermales system zur gleichzeitigen verabreichung von mehreren wirkstoffen
Shah et al. Comparative evaluation of pre-emptive analgesic efficacy of intramuscular ketorolac versus tramadol following third molar surgery
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
ATE414522T1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
Wilkinson et al. Centrally acting vasopressin contributes to endotoxin tolerance
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.